Acne Cure News

New Novel Compounds Archives

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Olumacostat glasaretil (OG) inhibits acetyl-coenzyme A carboxylase, the enzyme responsible for the first, rate-limiting step in de novo fatty acid synthesis. OG inhibited in vitro human sebocyte lipid production and reduced in vivo sebaceous gland size in hamster ears. Safety and efficacy of OG 7.5% gel were evaluated in patients with moderate to severe facial acne vulgaris.

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials

The objective of this study was to assess the efficacy and safety of a new, once-daily formulation of dapsone gel, 7.5%, with a 50% higher dapsone concentration, versus vehicle over 12 weeks in patients with acne.

BioPharmX completes enrollment in study of topical minocycline gel to treat acne

BiopharmX Corp. recently announced in a press release that it has completed enrollment in a phase 2a study of BPX-01, a novel topical minocycline gel to treat acne. “This research is important in the dermatology community, which has been searching for an effective alternative to current oral antibiotic acne treatments,” AnnMarie Daniels, executive vice president of clinical and regulatory affairs for BioPharmX, stated in the release.

Five recent developments in acne.

The FDA’s approval of Allergan plc’s Aczone Gel, 7.5% as a once-daily topical treatment for patients with acne was a recent development reported on Healio.com/Dermatology. Other recent developments included research presented at the American Academy of Dermatology Annual Meeting on acne treatment and the public’s misconceptions of patients with acne.

Zolav(®): a new antibiotic for the treatment of acne

Acne is a prominent skin condition affecting >80% of teenagers and young adults and ~650 million people globally. Isotretinoin, a vitamin A derivative, is currently the standard of care for treatment. However, it has a well-established teratogenic activity, a reason for the development of novel and low-risk treatment options for acne. Objective: To investigate the effectiveness of Zolav(®), a novel antibiotic as a treatment for acne vulgaris.